Schmitz Y, Schwerdtfeger M, Westmeier J, Littwitz-Salomon E, Alt M, Brochhagen L
Front Cell Infect Microbiol. 2022; 12:949036.
PMID: 36325470
PMC: 9618724.
DOI: 10.3389/fcimb.2022.949036.
Wilhelmus K
Cochrane Database Syst Rev. 2015; 1:CD002898.
PMID: 25879115
PMC: 4443501.
DOI: 10.1002/14651858.CD002898.pub5.
Wijesundara D, Xi Y, Ranasinghe C
Front Immunol. 2014; 5:412.
PMID: 25221557
PMC: 4148647.
DOI: 10.3389/fimmu.2014.00412.
Wilhelmus K
Cochrane Database Syst Rev. 2010; (12):CD002898.
PMID: 21154352
PMC: 4739528.
DOI: 10.1002/14651858.CD002898.pub4.
Borden E, Sen G, Uze G, Silverman R, Ransohoff R, Foster G
Nat Rev Drug Discov. 2007; 6(12):975-90.
PMID: 18049472
PMC: 7097588.
DOI: 10.1038/nrd2422.
The treatment of herpes simplex virus epithelial keratitis.
Wilhelmus K
Trans Am Ophthalmol Soc. 2001; 98:505-32.
PMID: 11190039
PMC: 1298240.
Pharmacokinetic properties of human fibroblast and leukocyte interferon in rabbits.
Vilcek J, Sulea I, Zerebeckyj I, Yip Y
J Clin Microbiol. 1980; 11(1):102-5.
PMID: 7354125
PMC: 273326.
DOI: 10.1128/jcm.11.1.102-105.1980.
Biosynthetic human interferon treatment of herpetic keratitis.
Smolin G
Trans Am Ophthalmol Soc. 1983; 81:785-824.
PMID: 6676984
PMC: 1312468.
Oral acyclovir in the management of dendritic herpetic corneal ulceration.
Hung S, Patterson A, Clark D, Rees P
Br J Ophthalmol. 1984; 68(6):398-400.
PMID: 6372855
PMC: 1040361.
DOI: 10.1136/bjo.68.6.398.
Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.
Richards D, Carmine A, Brogden R, Heel R, Speight T, Avery G
Drugs. 1983; 26(5):378-438.
PMID: 6315332
DOI: 10.2165/00003495-198326050-00002.
Interferons and viral infections.
Higgins P
Eur J Clin Microbiol. 1984; 3(4):282-4.
PMID: 6208021
PMC: 7087989.
DOI: 10.1007/BF01977473.
Effect of hyaluronidase on cell response to the antiviral and interferon inducing activity of poly(rI) . poly(rC).
Romano A, Ladijinsky E, Aboud M
Arch Virol. 1983; 78(3-4):315-9.
PMID: 6197954
DOI: 10.1007/BF01311328.
Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine.
de Koning E, van Bijsterveld O, Cantell K
Br J Ophthalmol. 1982; 66(8):509-12.
PMID: 6179534
PMC: 1039837.
DOI: 10.1136/bjo.66.8.509.
Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.
Pollard R
Drugs. 1982; 23(1-2):37-55.
PMID: 6173188
DOI: 10.2165/00003495-198223010-00002.
Antiviral agents: an update--Part 2.
Ogra P
Indian J Pediatr. 1980; 47(389):515-22.
PMID: 6167513
DOI: 10.1007/BF02822541.
Interferon: therapeutic fact or fiction for the '80s?.
Scott G, Tyrrell D
Br Med J. 1980; 280(6231):1558-62.
PMID: 6159043
PMC: 1601917.
DOI: 10.1136/bmj.280.6231.1558.
Comparative evaluation of human leukocyte and fibroblast interferon in the prevention of herpes simplex virus keratitis in a monkey model.
Neumann-Haefelin D, Sundmacher R, Skoda R, Cantell K
Infect Immun. 1977; 17(2):468-70.
PMID: 408274
PMC: 421145.
DOI: 10.1128/iai.17.2.468-470.1977.
Advances in antiviral chemotherapy.
Buchanan R
Can Med Assoc J. 1979; 120(1):7-10.
PMID: 367558
PMC: 1818806.
Interferons: anti-neoplastic drugs?.
Strander H
Blut. 1977; 35(4):277-88.
PMID: 334285
DOI: 10.1007/BF00996140.
Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis.
Sundmacher R, Cantell K, Skoda R, Hallermann C, Neumann-Haefelin D
Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978; 208(4):229-33.
PMID: 310269
DOI: 10.1007/BF00419377.